Literature DB >> 11960321

MCL1 provides a window on the role of the BCL2 family in cell proliferation, differentiation and tumorigenesis.

R W Craig1.   

Abstract

The MCL1 gene (myeloid cell leukemia-1) was discovered serendipitously about a decade ago and proved to be a member of the emerging BCL2 gene family. Ongoing studies of this gene provide an interesting perspective on the role of the BCL2 family in transitions in cell phenotype. Specifically, gene products that influence cell viability as a major effect (eg MCL1, BCL2 and other family members) can act as key determinants in cell proliferation, differentiation and tumorigenesis. Although they do not have a direct role in proliferation/differentiation programs, these genes can either permit these programs to proceed or prevent them. Through such effects, the BCL2 family regulates the normal flow of cells through cycles of proliferation and along various pathways of differentiation. A model is presented suggesting that this is accomplished by sustaining or inhibiting viability at critical points in the cell lifecycle. These critical points represent windows of time during which cell fate transitions are effected. They can also be visualized as windows that open or close to promote or prevent continued progression along various cell fate pathways. The pattern of BCL2 family expression at these points allows for the proliferation differentiation, and continued viability of cell types that are needed, while aborting these processes for cells that are overabundant or no longer needed. The combined action of the various family members can therefore control the fate of cells, tissues and even the organism. This mechanism involving apoptosis-related genes is readily executable, and is poised to respond to external signals through the differential regulation of BCL2 family members. As such, it plays an important role in the maintenance of tissue homeostasis and function. Alterations that affect the BCL2 family impair the capacity to control the flow of cells through these critical points, and thereby 'leave the window open' for cell immortalization and cancer. Targeting this family may thus provide a means of inhibiting cancer development and inducing apoptosis in tumor cells.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11960321     DOI: 10.1038/sj.leu.2402416

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  99 in total

1.  Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors.

Authors:  Gregory J Gores; Scott H Kaufmann
Journal:  Genes Dev       Date:  2012-02-15       Impact factor: 11.361

2.  Upregulation of proapoptotic microRNA mir-125a after massive small bowel resection in rats.

Authors:  Anita Balakrishnan; Adam T Stearns; Peter J Park; Jonathan M Dreyfuss; Stanley W Ashley; David B Rhoads; Ali Tavakkolizadeh
Journal:  Ann Surg       Date:  2012-04       Impact factor: 12.969

3.  MCL1 increases primitive thymocyte viability in female mice and promotes thymic expansion into adulthood.

Authors:  Jingang Gui; Amanda J Morales; Sophie E Maxey; Katherine A Bessette; Nora R Ratcliffe; John A Kelly; Ruth W Craig
Journal:  Int Immunol       Date:  2011-09-21       Impact factor: 4.823

Review 4.  Bodyguards and assassins: Bcl-2 family proteins and apoptosis control in chronic lymphocytic leukaemia.

Authors:  Graham Packham; Freda K Stevenson
Journal:  Immunology       Date:  2005-04       Impact factor: 7.397

5.  High expression of Mcl-1 in ALK positive and negative anaplastic large cell lymphoma.

Authors:  R Rust; G Harms; T Blokzijl; M Boot; A Diepstra; J Kluiver; L Visser; S-C Peh; M Lim; W A Kamps; S Poppema; A van den Berg
Journal:  J Clin Pathol       Date:  2005-05       Impact factor: 3.411

6.  The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized.

Authors:  Mark F van Delft; Andrew H Wei; Kylie D Mason; Cassandra J Vandenberg; Lin Chen; Peter E Czabotar; Simon N Willis; Clare L Scott; Catherine L Day; Suzanne Cory; Jerry M Adams; Andrew W Roberts; David C S Huang
Journal:  Cancer Cell       Date:  2006-11       Impact factor: 31.743

7.  Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer.

Authors:  Qingqing Ding; Longfei Huo; Jer-Yen Yang; Weiya Xia; Yongkun Wei; Yong Liao; Chun-Ju Chang; Yan Yang; Chien-Chen Lai; Dung-Fang Lee; Chia-Jui Yen; Yun-Ju Rita Chen; Jung-Mao Hsu; Hsu-Ping Kuo; Chun-Yi Lin; Fuu-Jen Tsai; Long-Yuan Li; Chang-Hai Tsai; Mien-Chie Hung
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

Review 8.  Mitosis as an anti-cancer drug target.

Authors:  Anna-Leena Salmela; Marko J Kallio
Journal:  Chromosoma       Date:  2013-06-18       Impact factor: 4.316

9.  Cell death of bioenergetically compromised and transcriptionally challenged CLL lymphocytes by chlorinated ATP.

Authors:  Kumudha Balakrishnan; Christine M Stellrecht; Davide Genini; Mary Ayres; William G Wierda; Michael J Keating; Lorenzo M Leoni; Varsha Gandhi
Journal:  Blood       Date:  2005-02-17       Impact factor: 22.113

10.  Inhibition of protein phosphatase 2A (PP2A) prevents Mcl-1 protein dephosphorylation at the Thr-163/Ser-159 phosphodegron, dramatically reducing expression in Mcl-1-amplified lymphoma cells.

Authors:  Shanna K Nifoussi; Nora R Ratcliffe; Deborah L Ornstein; Gary Kasof; Stefan Strack; Ruth W Craig
Journal:  J Biol Chem       Date:  2014-06-17       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.